On April 30, Twining Biotech raised the 20cm large limit. The concept of synthetic biology continued to be strong, and Blue Biotech walked out of the three boards, and Boen Group, Luculent Environment, Fuxiang Pharmaceutical, and Jiabiyou rose first.
On the news side, Chuanning Biotech recently said on the interactive platform that the company has provided a large number of production data to Jinhui Technology, and the AI model has made corresponding analysis and intelligent improvement plans, and according to the data for professional model construction, it has been verified in the company, providing us with new ideas in process optimization ideas, and in front-end research, AI has significantly improved the construction of key enzymes, enzyme activity and R&D efficiency. The market demand for the company's main products is strong, the orders are full, and the capacity utilization rate remains high.
The agency believes that biomanufacturing is the key development direction of the bioeconomy, the trillion-dollar track is about to emerge, and the national and local policies are frequently implemented, and the industrialization of biomanufacturing is expected to accelerate.
Introduction and main business of Twining Biotech
Twining Biotech's current products mainly include erythromycin thiocyanate, cephalosporin intermediates (7-ACA, D-7ACA and 7-ADCA), penicillin intermediates (6-APA and penicillin G potassium salt) and crude ursodeoxycholic acid. The company is one of the large-scale enterprises in the industrial application of biological fermentation technology in China, and one of the enterprises with leading scale, complete product types and advanced production technology in the field of antibiotic intermediates. Since its establishment, the company has always focused on technological innovation in the field of biological fermentation, especially the innovation and improvement of the production process of antibiotic intermediates fermentation, and has continued to work hard and develop to lead the technological development of the industry. The company's innovation has achieved many honors, the company was selected by the Ministry of Industry and Information Technology in 2017 the first batch of green manufacturing system demonstration list, becoming the first selected pharmaceutical enterprise in Xinjiang, the company was selected by the Ministry of Industry and Information Technology of the Ministry of Industry and Information Technology of the Ministry of Industry and Information Technology of the Ministry of Industry and Information Technology of the People's Republic of China Intelligent Manufacturing Comprehensive Standardization and New Model Application Project List, the company won the title of "Twelfth Five-Year National Light Industry Science and Technology Innovation Advanced Collective" in 2016, and became the fourth batch of circular economy pilot enterprises in Xinjiang Uygur Autonomous Region, and was recognized as an enterprise technology center by the Science and Technology Department of Xinjiang Uygur Autonomous Region.
The concept of Twining Biotech stocks
Biological products, ursodeoxycholic acid, biomedicine, AI pharmaceuticals, Xinjiang plate, Shenzhen Cheng 500, pre-profit and pre-increase, margin financing and securities lending, the Belt and Road, ChiNext Comprehensive, Shenzhen-Hong Kong Stock Connect.
What is the status of Twining Biotech in the industry?
From the perspective of operating income, Twining Biotech is lower than the industry average, ranking 84th in the industry.
What is the basic situation of Twining Biotech's stock issuance?
The total share capital of Twining Biotech is 2.223 billion shares, of which 613 million A shares are outstanding. As of April 30, the total market capitalization was 29,296.5 million, the circulating market value was 8,078.2 million yuan, and the price-earnings ratio was 26.21. The number of shareholders is 31,600. The largest shareholder is Sichuan Kelun Pharmaceutical Co., Ltd., with the top ten shareholders accounting for 87.15% of the shares.
What about the financial data of Twining Biotech stock?
According to the first quarter report of 2024, the total revenue of Twining Biotech was 1.523 billion yuan, and the net profit attributable to the parent company was 353 million yuan, with a year-on-year increase of 19.96% in total revenue and a year-on-year increase of 100.98% in attributable net profit.
As of December 31, 2023, by industry, the operating income of the pharmaceutical manufacturing industry was 4.515 billion, and the revenue ratio was 93.60%.
Executive profiles
Liu Xinxin: male, born in 1951, Chinese nationality, no right of abode abroad, postgraduate degree, senior engineer, general manager of Sichuan Qili Pharmaceutical Co., Ltd. in 1992, founded Kelun Pharmaceutical Factory in 1996, and served as the chairman of Kelun Pharmaceutical Co., Ltd. From 1996 to 2003, he served as the general manager of Kelun Pharmaceutical, and successively served as the vice president of the Sichuan Federation of Industry and Commerce, a standing member of the 9th Sichuan Provincial Committee of the Chinese People's Political Consultative Conference, a representative of the 9th Sichuan Provincial Congress of the Communist Party of China, a member of the 11th National Committee of the Chinese People's Political Consultative Conference, a representative of the 12th Chengdu Congress of the Communist Party of China, a representative of the 10th Sichuan Provincial Congress of the Communist Party of China, and a representative of the 12th National People's Congress. In 2005, he was awarded the honorary title of "National Model Worker", in 2008, he was awarded the honorary title of "Outstanding Communist Party Member for Earthquake Relief" by the Sichuan Provincial Committee of the Communist Party of China and the Chengdu Municipal Party Committee, and the honorary title of "Model Earthquake Relief" awarded by the Sichuan Provincial Party Committee and the Provincial Government; in 2009, he was awarded the title of "Outstanding Builder of Socialism with Chinese Characteristics" by the United Front Work Department of the CPC Central Committee, the Ministry of Industry and Information Technology, the Ministry of Human Resources and Social Security, the State Administration for Industry and Commerce, and the All-China Federation of Industry and Commerce. In 2015, he won the National Science and Technology Progress Award as the first person to complete the project, and in 2018, he was rated as an outstanding private entrepreneur in Sichuan Province by the Sichuan Provincial Committee of the Communist Party of China and the Sichuan Provincial People's Government, and won the "Sichuan Poverty Alleviation Dedication Award" by the Sichuan Provincial Leading Group for Poverty Alleviation. He is currently the chairman of the board of directors of the company, the chairman and secretary of the party committee of Sichuan Kelun Pharmaceutical Co., Ltd., the chairman of Sichuan Kelun Industrial Group Co., Ltd., and the director of Chengdu Huaxi Clinical Research Center Co., Ltd.
Huaan Securities: The biomanufacturing policy is expected to be introduced in the near future, and the synthetic biology industry has ushered in an important inflection point
At the 2024 Zhongguancun Forum Annual Meeting on April 26, Tan Tianwei, President of Beijing University of Chemical Technology and Academician of the Chinese Academy of Engineering, mentioned that at present, led by the National Development and Reform Commission, the Ministry of Industry and Information Technology and the Ministry of Science and Technology and other national ministries and commissions are jointly developing a national biotechnology and biomanufacturing action plan, and it is expected to be introduced in the near future, and "biomanufacturing +" is the key content.
Biomanufacturing is the key development direction of the bioeconomy, and the trillion-dollar track is about to emerge
Biomanufacturing (synthetic biology) is a new "creation" technology, which integrates biology, chemistry, engineering and other technologies, using renewable biomass as raw materials and organisms as production media, aiming to use cheap raw materials, strain, cells, and enzymes as manufacturing plants to obtain target products through large-scale fermentation, which has the characteristics of clean, efficient and renewable. According to the second interpretation of the government's "14th Five-Year Plan" bioeconomic development plan, the biomanufacturing industry is the key development direction of the bioeconomy, and 35% of petrochemical and coal chemical products will be replaced by biomanufacturing products in the next ten years. The World Wide Fund for Nature (WWF) estimates that biomanufacturing technologies could reduce CO2 emissions by 1 billion to 2.5 billion tonnes per year by 2030. According to the "Synthetic Biology: Global Market" report released by BCC Research, a U.S. market research company, in 2020, the global market size directly driven by synthetic biology reached US$5.319 billion in 2019 and is expected to reach US$18.885 billion in 2024, with a compound annual growth rate of 28.8% from 2019 to 2024. According to the 2020 MGI research report "Biological Revolution: Innovation Transforms Economy, Society and People's Lives", it is estimated that in the next 10~20 years, synthetic biology related applications may have a direct economic impact of 2~4 trillion US dollars per year on the world. In the future, biomanufacturing is expected to become the fourth industrial wave after the agricultural economy, industrial economy, and digital economy, and is expected to open up a trillion-scale market space.
Policies at the national and local levels have been implemented frequently, and the industrialization of biomanufacturing is expected to accelerate
In 2022, the National Development and Reform Commission (NDRC) issued the "14th Five-Year Plan for the Development of the Bioeconomy" to promote technological innovation in synthetic biology. Since 2023, many places across the country have issued special policy documents for the high-quality development of the synthetic biology industry to accelerate the industrialization of biomanufacturing. When deploying the government's work tasks in 2024, Premier Li Qiang said that the country should actively cultivate emerging industries and future industries, accelerate the development of innovative drugs and other industries, actively build new growth engines such as biomanufacturing, commercial aerospace, and low-altitude economy, formulate future industrial development plans, open up new tracks such as life sciences, and create a number of future industry pilot areas. Biomanufacturing is regarded as a very important new track and new format of new quality productivity, and the policy side continues to promote the industrialization of biomanufacturing, and is expected to be introduced in the near future, led by the National Development and Reform Commission, the Ministry of Industry and Information Technology and the Ministry of Science and Technology and other national ministries and commissions are jointly developing a national biotechnology and biomanufacturing action plan, which is expected to further accelerate the industrialization of biomanufacturing.
Risk Warning:
The risk of industrialization process is less than expected, the risk of strain and formula leakage, the risk of legal action, the risk of biosecurity, the risk of ethics and ethics, and the risk of downstream certification not as expected.
Source:
Huaan Securities-Biomanufacturing Industry Comments: Biomanufacturing policies are expected to be introduced in the near future, and the synthetic biology industry has ushered in an important inflection point.-20240428
Investment advisory support: Yu Xiaoming Practicing certificate number: A0680622030012
Disclaimer: The above content is for reference only and does not constitute specific operation advice, and you shall operate at your own risk and profit and loss.